Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with radiotherapy in previously treated extensive-stage small cell lung cancer
ChiCTR1900021820Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in small cell lung cancer (SCLC), sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Primary endpoint: overall survival. Started Jun 2019; status: recruiting.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR1900021820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021820.